Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Oregon
Clinical trial register · United States · industry-sponsored

Clinical Trials in Oregon, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca14 Novartis Pharmaceuticals12 Bristol-Myers Squibb9 AbbVie8 Janssen Research & Development, LLC8
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Oregon

345 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Talk Parenting Education Program II
NCT07462052Parenting Practices, Self Efficacy, Stress, Child Behavior
Oregon Research Behavioral Intervention Strategies, Inc.
Not applicable
184
Oregon
2026-11-01
Not yet open
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
NCT07793942Malignant Neoplam, Advanced Solid Tumors
DrugsMK-2010·Belzutifan·Fluorouracil·Leucovorin
Merck Sharp & Dohme LLC
Phase 2
480
New Jersey, Ohio, Oregon
2026-10-27
Not yet open
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
NCT07578649Endometrial Neoplasms, Endometrial Cancer
DrugsPF-08634404·Keytruda·Pembrolizumab
Pfizer
Phase 3
600
Florida, Minnesota, Nevada, Ohio, Oregon, Tennessee, Texas, Virginia
2026-10-09
Not yet open
Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease
NCT07675408Parkinson's Disease With Freezing of Gait
Fortis Medical Devices Limited
Not applicable
60
Florida, Georgia, Kansas, Oregon, Washington
2026-10
Not yet open
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT07807969Geographic Atrophy
DrugVonaprument
Annexon, Inc.
Phase 3
605
Florida, Maryland, Massachusetts, North Carolina, Oregon
2026-09-30
Recruiting
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
NCT07700979Gastric / Gastroesophageal Junction Adenocarcinoma
DrugsFolfox·Cadonilimab·Nivolumab
Akeso
Phase 3
900
Arizona, California, Colorado, Connecticut, Massachusetts, Michigan, New York, Oregon
2026-09-24
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
DrugsPatritumab deruxtecan·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 1/2
220
California, Colorado, Connecticut, Massachusetts, New York, Oregon, Tennessee, Texas
2026-09-17
Recruiting
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
NCT07412704Arthritis, Rheumatoid
Bristol-Myers Squibb
Phase 1/2
84
California, Colorado, Florida, New York, Oregon, Pennsylvania, Texas
2026-09-15
Recruiting
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
NCT07543055Prostate Cancer
Regeneron Pharmaceuticals
Phase 1
36
Georgia, New Jersey, Oregon
2026-09-08
Recruiting
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
NCT07814248NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer
TwoStep Therapeutics, Inc.
Phase 1
74
Ohio, Oregon, Virginia
2026-09-02
Recruiting
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
NCT07645248Asthma
GlaxoSmithKline
Phase 3
110
Florida, Kentucky, Missouri, Nevada, Oregon, South Carolina, Texas
2026-09-01
Not yet open
A Trial to Assess the Safety and Effectiveness of an Anatomic Total Shoulder System
NCT07812324Shoulder Arthroplasty, Total Shoulder Arthroplasty
Medacta USA
Not applicable
286
Arizona, Florida, Indiana, Maryland, New Hampshire, New York, Oregon, Pennsylvania
2026-09
Recruiting
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
NCT07569926Prostate Cancer
DrugPiflufolastat
Blue Earth Diagnostics
Phase 4
142
California, Georgia, Massachusetts, Missouri, Oregon, Texas
2026-08-31
Recruiting
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
NCT07816185Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 3
376
Florida, Kentucky, Oregon
2026-08-31
Recruiting
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
NCT07770841Overweight, Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 3
450
Alabama, California, Florida, Hawaii, Kentucky, Missouri, Nevada, Oregon
2026-08-12
Recruiting
Reduction or Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US)
NCT07130994Mitral Regurgitation, Heart Disease
InnovHeart
Not applicable
15
California, New York, Oregon
2026-08-05
Recruiting
Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation
NCT07335523Exocrine Pancreatic Insuficiency
Digestive Care, Inc.
Observational
30
Colorado, New York, Ohio, Oregon, Tennessee, Texas, Washington
2026-08-03
Recruiting
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
NCT07520006B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBexobrutideg·Obinutuzumab·Venetoclax·Rituximab
Nurix Therapeutics, Inc.
Phase 1/2
150
Colorado, Florida, Oregon, Pennsylvania, Tennessee, Texas
2026-08
Recruiting
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
NCT07688213Dementia, Alzheimer's Type, Alzheimer's Disease
Sanofi
Phase 2
160
California, Florida, Massachusetts, New Jersey, Oregon, Pennsylvania, Texas
2026-07-28
Recruiting
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
NCT07586202Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 2
68
California, Oregon
2026-07-28
Recruiting
Safety and Efficacy of J147 in Acute Ischemic Stroke
NCT07430917Acute Ischemic Stroke
Abrexa Pharmaceuticals, Inc.
Phase 2
196
California, Illinois, New York, Oregon, Texas
2026-07-22
Recruiting
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07234032Pulmonary Hypertension, Interstitial Lung Disease
DrugTreprostinil Palmitil
Insmed Incorporated
Phase 3
344
Florida, Oregon
2026-07-20
Recruiting
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
NCT07690436Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Observational
500
California, Florida, Illinois, Massachusetts, Oregon, Tennessee
2026-07-08
Recruiting
A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
NCT07348666Suicide, Mental Health Disorder, Anhedonia
Ksana Health
Not applicable
100
Oregon, Pennsylvania
2026-06-18
By invitation
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
NCT07734415Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
DrugIMG-007
Inmagene LLC
Phase 2
400
California, Florida, Illinois, New York, North Carolina, North Dakota, Ohio, Oregon
2026-06-05
Recruiting
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
NCT07590934Metastatic Prostate Cancer
DrugsAZD2287·FPI-2265·Palacaparib·Docetaxel
AstraZeneca
Phase 1/2
152
California, Florida, Louisiana, Minnesota, Nebraska, New York, Oregon, Texas
2026-06-03
Recruiting
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
NCT07646587COPD (Chronic Obstructive Pulmonary Disease)
DrugWIN378
Windward Bio
Phase 2
105
California, Florida, Massachusetts, North Carolina, Oregon, Pennsylvania, Texas
2026-06-02
Recruiting
Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
NCT07477691Phenylketonuria
DrugsPegvaliase·Methotrexate
BioMarin Pharmaceutical
Phase 4
12
California, Colorado, Florida, Illinois, Indiana, Minnesota, New York, Oregon
2026-05-29
Recruiting
Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency
NCT07636590Limbal Stem Cell Deficiency
Claris Biotherapeutics, Inc.
Observational
500
Indiana, Kansas, Kentucky, Minnesota, Oregon, Tennessee, Texas
2026-05-22
Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156Urothelial Cancer, Urinary Bladder Neoplasms
DrugsMitomycin C·Enfortumab Vedotin·Fluorouracil·Keytruda
Astellas Pharma Global Development, Inc.
Phase 3
390
California, Colorado, Delaware, Illinois, Indiana, Missouri, Ohio, Oregon
2026-05-11
Not yet open
Technology Development of Diagnostic Ultrasound System for Obstetric Imaging
NCT07590063Pregnancy
United Imaging Healthcare North America, Inc.
Observational
50
Oregon
2026-05-06
Recruiting
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
NCT07286149Lung Neoplasm Malignant
DrugsCalderasib·Patritumab deruxtecan·Erbitux·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 1/2
140
Florida, Illinois, Oregon
2026-04-30
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Arizona, California, Colorado, Florida, Illinois, Indiana, New York, Oregon
2026-04-23
Recruiting
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
NCT07558733HR+ HER2- Breast Cancer
DrugsSerabelisib·Sapanisertib·Fulvestrant
Faeth Therapeutics
Phase 1/2
32
California, Colorado, Oregon, Tennessee, Texas
2026-04-22
Recruiting
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
NCT07546500Ovarian Cancer
DrugAzenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Arizona, California, New Jersey, Ohio, Oregon, Pennsylvania, South Dakota
2026-04-17
By invitation
A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle Glaucoma
NCT07520175Open-Angle Glaucoma
Iantrek, Inc.
Observational
300
California, Minnesota, Oregon, Pennsylvania, Texas
2026-04-01
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
DrugsPumitamig·Yervoy·Ipilimumab
Bristol-Myers Squibb
Phase 1/2
198
California, Illinois, Michigan, New Jersey, New York, Oregon, Tennessee, Washington
2026-03-16
Recruiting
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
NCT07235917Functional Hypothalamic Amenorrhea, FHA
DrugMibavademab
Regeneron Pharmaceuticals
Phase 2
34
Arizona, California, Connecticut, Florida, Oregon, Pennsylvania, Texas, Virginia
2026-03-11
Recruiting
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
NCT07408232Retinitis Pigmentosa
Octant, Inc.
Phase 1/2
18
Oregon, Texas
2026-03-10
Recruiting
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
NCT07226895Clinical High Risk for Psychosis (CHR)
Monument Therapeutics Limited
Phase 1/2
150
California, Connecticut, Massachusetts, Missouri, New York, North Carolina, Ohio, Oregon
2026-03-03
Recruiting
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
NCT07285785Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
DrugRifaximin
Bausch Health Americas, Inc.
Phase 4
54
California, Florida, Georgia, Illinois, Oregon, Texas, Virginia
2026-02-11
Recruiting
A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System
NCT07118501Post Traumatic Arthritis, Osteoarthritis, Total Ankle Replacement, Total Ankle Prosthesis
Stryker Trauma and Extremities
Observational
200
Illinois, Indiana, Kentucky, Oregon, South Carolina
2026-02-06
Recruiting
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
NCT07284472Agitation Associated With Alzheimer's Disease Dementia
Exciva GmbH
Phase 2/3
300
California, Indiana, Mississippi, Missouri, New York, Ohio, Oregon, Vermont
2026-02-02
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Arkansas, California, Colorado, Florida, New Jersey, New York, Oregon, Texas
2026-01-30
Recruiting
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597Small Cell Lung Cancer Extensive Stage
DrugsGocatamig·Ifinatamab Deruxtecan·Etoposide·Atezolizumab
Merck Sharp & Dohme LLC
Phase 1/2
170
California, Colorado, Florida, Kentucky, Missouri, New Jersey, Oregon, South Dakota
2026-01-29
Active, closed
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860Dermatitis, Atopic
Janssen Research & Development, LLC
Phase 2
189
California, Florida, Illinois, Indiana, Michigan, North Dakota, Oregon, Pennsylvania
2026-01-20
Recruiting
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
NCT06809114Solid Tumor
Axcynsis Therapeutics Pte Ltd
Phase 1
83
Oregon
2026-01-14
Recruiting
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
NCT07155226Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
DrugPosaconazole
AstraZeneca
Phase 1/2
84
Illinois, New York, North Carolina, Oregon, Texas
2026-01-09
Recruiting
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380Pulmonary Hypertension, Interstitial Lung Disease
DrugTreprostinil Palmitil
Insmed Incorporated
Phase 3
344
Arizona, California, Florida, Kansas, New York, North Carolina, Ohio, Oregon
2026-01-07
Active, closed
Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management
NCT06420245Diabetic Foot Ulcer
Legacy Medical Consultants
Not applicable
240
California, Connecticut, Florida, Illinois, Maryland, Oregon
2025-12-30
Recruiting
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
NCT07315113EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients
DrugsNXP900·Osimertinib
Nuvectis Pharma, Inc.
Phase 1
18
Maryland, Massachusetts, Oregon, Pennsylvania, Texas, Virginia
2025-12-18
Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
NCT07194070Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Observational
175
Indiana, New York, Ohio, Oregon, Texas
2025-12-17
Recruiting
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
NCT07052929X-Linked Myotubular Myopathy
DrugsSirolimus·Methylprednisolone·Prednisolone
Astellas Gene Therapies
Phase 1/2
9
Illinois, Massachusetts, Oregon, Texas
2025-12-15
Recruiting
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
NCT07062588Osteogenesis Imperfecta (OI)
DrugAGA2115
Angitia Incorporated Limited
Phase 2
80
Arizona, Connecticut, Delaware, Indiana, Missouri, New Mexico, Ohio, Oregon
2025-12-12
Recruiting
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
NCT07221474Squamous Non-small Cell Lung Cancer
DrugsIntismeran autogene·Nab-paclitaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 2
180
Florida, Michigan, Missouri, New Jersey, New York, Ohio, Oregon, Tennessee
2025-12-12
Recruiting
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT07216443Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
DrugOrca-T
Orca Biosystems, Inc.
Phase 2
80
California, Florida, New Jersey, New York, Oregon, Tennessee
2025-12-09
Recruiting
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
NCT07165132GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
RayzeBio, Inc.
Phase 1
104
Arizona, Florida, Iowa, Kentucky, Minnesota, Missouri, Ohio, Oregon
2025-12-03
Recruiting
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT06930625Acromegaly
Debiopharm International SA
Phase 3
119
California, Illinois, Massachusetts, Missouri, Nevada, New York, Ohio, Oregon
2025-11-26
Recruiting
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
NCT07205718Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2
223
California, Connecticut, Florida, Maryland, Michigan, Missouri, Ohio, Oregon
2025-11-19
Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
NCT07144345Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 3
160
California, Florida, Illinois, Indiana, Minnesota, Missouri, Oregon, South Carolina
2025-11-19
By invitation
Impact of Anatomy-Based Cochlear Implant Programming on Early Performance
NCT06734039Hearing Loss, Unilateral, Cochlear Implants, Hearing Loss, Sensorineural, Single-Sided Deafness (SSD)
Med-El Corporation
Not applicable
50
Iowa, Kansas, North Carolina, Oregon, Pennsylvania
2025-11-10
Recruiting
Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain
NCT07226258Osteoarthritis Knee Pain
Saol Therapeutics Inc
Phase 3
150
California, Colorado, District of Columbia, Florida, Minnesota, North Carolina, Oklahoma, Oregon
2025-11-07
Recruiting
Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment and Reduction of Heavy Drinking in Individuals With of Alcohol Use Disorder (AUD)
NCT07216872Alcohol Use Disorder, Alcoholism, Alcohol Abuse, Alcohol Dependence
Brainsway
Not applicable
186
Alabama, California, Florida, Illinois, New York, Ohio, Oregon, West Virginia
2025-11-07
Recruiting
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
NCT07203001Still´s Disease
DrugArumakimig
Novartis Pharmaceuticals
Phase 2
30
Ohio, Oregon, Utah
2025-11-03
Recruiting
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
NCT07007962Immune Thrombocytopenia
DrugRilzabrutinib
Sanofi
Phase 3
60
California, Louisiana, Massachusetts, Michigan, Minnesota, New York, Oregon, Utah
2025-10-24
Recruiting
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
NCT07218887BAG3 Mutation Associated Dilated Cardiomyopathy
Alexion Pharmaceuticals, Inc.
Phase 1/2
6
Alabama, California, Massachusetts, Ohio, Oregon, Pennsylvania, Texas
2025-10-24
Recruiting
A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy
NCT07127978Duchene Muscular Dystrophy
ITF Therapeutics LLC
Observational
300
Arkansas, District of Columbia, Illinois, Massachusetts, New York, North Carolina, Oregon, Washington
2025-10-23
Recruiting
A Study of JNT-517 in Participants With Phenylketonuria (PKU)
NCT06971731Phenylketonuria
DrugRepinatrabit
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
120
California, Florida, Illinois, Oregon, Pennsylvania, Tennessee, Texas, Utah
2025-10-20
Recruiting
Z1 Hip System: Post-Market Clinical Follow Up Study
NCT07104279Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck, Avascular Necrosis of the Femoral Head
Zimmer Biomet
Observational
300
North Carolina, Ohio, Oregon, Virginia
2025-10-13
Recruiting
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2
140
Missouri, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Washington
2025-10-09
Recruiting
Clinical Course Of Disease In Participants With FA-CM
NCT06865482Friedreich Ataxia, Cardiomyopathy
Lexeo Therapeutics
Observational
65
California, Florida, Indiana, Massachusetts, Minnesota, Missouri, Ohio, Oregon
2025-09-30
Recruiting
Pivotal Study on the NOVABLOC System for Patients Undergoing Primary Total Knee Arthroplasty
NCT07191067Pain
Synaptrix, Inc.
Not applicable
120
Alabama, New York, North Carolina, Oregon, Washington
2025-09-30
Recruiting
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
NCT06751238Juvenile Psoriatic Arthritis
DrugSecukinumab
Novartis Pharmaceuticals
Phase 1
20
California, Florida, Illinois, New York, North Carolina, Ohio, Oregon, Pennsylvania
2025-09-24
Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer
Pheon Therapeutics
Phase 1
165
California, District of Columbia, Massachusetts, Missouri, North Carolina, Oregon, Tennessee, Texas
2025-09-23
Recruiting
At Home Ammonia Monitoring of Inborn Errors of Ammonia Metabolism
NCT06953505Urea Cycle Disorders, Organic Acidemias, Fatty Acid Oxidation Disorder, Ammonia; Metabolic Disorder
Sequitur Health Corp.
Not applicable
30
Oregon
2025-09-23
Recruiting
AMEND TS Early Feasibility Study
NCT06951672Symptomatic Functional MR 3 or Greater
Valcare Medical Ltd.
Not applicable
15
Arizona, California, Georgia, Indiana, New York, Oregon, Tennessee, Texas
2025-09-11
Recruiting
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
NCT07013201Palmoplantar Pustulosis
DrugDelgocitinib
LEO Pharma
Phase 2
135
California, Georgia, Michigan, New York, Ohio, Oregon, Pennsylvania
2025-09-11
Active, closed
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
NCT07174726X-Linked Retinitis Pigmentosa (XLRP)
Beacon Therapeutics
Phase 2
10
Florida, North Carolina, Ohio, Oregon, Texas
2025-09-10
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
DrugsNavlimetostat·Iza-bren
Bristol-Myers Squibb
Phase 2
182
Alaska, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon, Washington
2025-09-09
Recruiting
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT07085091NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
ALX Oncology Inc.
Phase 1
170
California, Florida, Michigan, New Jersey, Ohio, Oregon, Texas, Utah
2025-08-18
Active, closed
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
NCT06985147Polycythemia Vera (PV)
DrugDISC-3405
Disc Medicine, Inc
Phase 2
60
Arizona, California, Florida, Minnesota, Missouri, North Carolina, Ohio, Oregon
2025-08-12
Recruiting
A Long-Term Study of JNT-517 in Participants With Phenylketonuria
NCT06628128Phenylketonuria (PKU)
DrugRepinatrabit
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
240
Florida, Oregon, Pennsylvania, Texas, Utah
2025-08-11
Recruiting
FiberLocker® System Augmentation of Rotator Cuff Repairs
NCT06918041Rotator Cuff Tear, Rotator Cuff Tears, Rotator Cuff Tears of the Shoulder
ZuriMED Technologies Inc.
Not applicable
60
Illinois, Maryland, North Carolina, Oregon
2025-08-05
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
NCT07024784Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
DrugsIMGN151·Olaparib·Bevacizumab·Carboplatin
AbbVie
Phase 2
377
California, Colorado, Minnesota, New Jersey, New York, Ohio, Oklahoma, Oregon
2025-07-30
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960Multiple Myeloma
DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone
AbbVie
Phase 1/2
325
California, Connecticut, Massachusetts, Michigan, New York, North Carolina, Oregon, Texas
2025-07-23
Recruiting
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
NCT07356453Advanced Solid Tumors
FoRx Therapeutics AG
Phase 1
40
California, Michigan, Missouri, Oregon, Texas, Virginia
2025-07-22
Recruiting
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089Solid Tumors
DrugsDB-1305/BNT325·Pumitamig
DualityBio Inc.
Phase 2
450
California, Colorado, Florida, Georgia, Maryland, Nebraska, New York, Oregon
2025-07-18
Recruiting
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NCT07075185Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type
Kelonia Therapeutics, Inc.
Phase 1
70
California, Florida, Georgia, Massachusetts, New Jersey, Oregon
2025-07-16
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
DrugIrinotecan
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Recruiting
Walk With Me (WWM) for Perinatal Grief
NCT07011940Grief, Post Traumatic Stress Disorder, Suicidal Ideation, Miscarriage
Oregon Research Behavioral Intervention Strategies, Inc.
Not applicable
300
Oregon
2025-07-13
Recruiting
Pure Impact Treatment to Strengthen and Tone Abdomen, Quadriceps and Glutes Muscles
NCT07094971Muscle Tone, Muscle Strength
Sofwave Medical LTD
Not applicable
44
Oregon
2025-07-11
Recruiting
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
NCT06915025Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugsIMNN-001·Niraparib·Olaparib·Paclitaxel
Imunon
Phase 3
500
Florida, Louisiana, Minnesota, Missouri, Oregon, South Dakota, Tennessee, Washington
2025-07-09
Not yet open
Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
NCT06973629Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis
Brainstorm-Cell Therapeutics
Phase 3
200
Arizona, California, Colorado, Florida, Illinois, Massachusetts, Minnesota, Oregon
2025-06-30
Recruiting
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
NCT06872684Aneurysm, Aneurysm, Intracranial
Stryker Neurovascular
Not applicable
183
Arizona, California, Florida, Kansas, Massachusetts, New York, Ohio, Oregon
2025-06-20
Recruiting
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
DrugIMG-007
Inmagene LLC
Phase 2
405
California, Florida, Illinois, New York, North Carolina, North Dakota, Ohio, Oregon
2025-06-17
Recruiting
Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
NCT07169409Opioid Use Disorder
Boulder Care
Phase 1
250
Oregon
2025-06-10
Active, closed
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
NCT06852963Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease, Eye Diseases Hereditary
PYC Therapeutics
Phase 1/2
17
Florida, Michigan, Oregon, Texas
2025-06-01
Recruiting
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06533579B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Vironexis Biotherapeutics Inc.
Phase 1/2
32
California, Colorado, Florida, Minnesota, New York, North Carolina, Ohio, Oregon
2025-05-30
Recruiting
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
NCT06626919Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases
DrugsAnitocabtagene Autoleucel·Fludarabine·Cyclophosphamide
Arcellx, Inc.
Phase 1
30
California, Florida, Michigan, Minnesota, New York, Ohio, Oregon, Pennsylvania
2025-04-30
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Alabama, California, Florida, Minnesota, Missouri, New Mexico, Ohio, Oregon
2025-04-11
Recruiting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259Multiple Sclerosis, Relapsing-Remitting
DrugsFingolimod·Ozanimod
Bristol-Myers Squibb
Phase 3
194
California, Florida, Illinois, Kentucky, New Jersey, Ohio, Oregon, Texas
2025-04-08
By invitation
Observational Study - TA- 2025-1
NCT07007897Astigmatism
Haag-Streit AG
Observational
100
Arizona, Oregon
2025-04-01
Active, closed
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
NCT06788912Lung Neoplasm Malignant
DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Ribociclib·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 2
60
Alabama, California, Colorado, Maryland, Oregon, Texas, Virginia
2025-03-20
Recruiting
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT06797635Breast Neoplasms, Breast Cancer
DrugsPatritumab deruxtecan·Doxorubicin Hydrochloride·Epirubicin·Adriamycin
Merck Sharp & Dohme LLC
Phase 2
372
California, Illinois, Montana, Oregon, Tennessee, Texas, Virginia
2025-03-20
Recruiting
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
NCT06950034Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2
Solu Therapeutics, Inc
Phase 1
105
California, Florida, Massachusetts, Minnesota, Oregon, Tennessee, Texas
2025-03-13
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
NCT06868290ANCA Associated Vasculitis (AAV)
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
126
Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina, Oregon
2025-03-13
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
DrugZugo-cel
CRISPR Therapeutics
Phase 1
80
California, Illinois, Iowa, Louisiana, Massachusetts, Missouri, North Carolina, Oregon
2025-03-10
Recruiting
INHANCE Stemless Reverse Shoulder IDE
NCT06323980Arthroplasty, Replacement, Shoulder
DePuy Orthopaedics
Not applicable
168
Florida, Massachusetts, Michigan, Missouri, North Carolina, Ohio, Oregon, Pennsylvania
2025-03-04
Active, closed
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483Breast Cancer
DrugZelenectide pevedotin
BicycleTx Limited
Phase 2
66
Maryland, Massachusetts, Missouri, New York, North Carolina, Oregon, Texas, Virginia
2025-03-03
Recruiting
Glycemic Metrics and Patterns in People With and Without Prediabetes
NCT06921902Pre Diabetes
Abbott Diabetes Care
Observational
2,000
Oregon
2025-02-28
Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137Small Cell Lung Cancer
DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab
Merck Sharp & Dohme LLC
Phase 1/2
327
Colorado, Florida, Illinois, Massachusetts, New Jersey, New York, Oregon, Tennessee
2025-02-27
Active, closed
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
NCT06770933Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Vantage Biosciences Ltd
Phase 2
100
California, Florida, Georgia, Maryland, Oregon, Pennsylvania, Virginia
2025-02-11
Recruiting
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
NCT06942572Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
Splice Bio
Phase 1/2
57
Colorado, Florida, Massachusetts, Oregon, Texas
2025-02-11
Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287Lung Cancer, Breast Cancer
DrugsPumitamig·Iza-bren·Osimertinib·Opdivo
Bristol-Myers Squibb
Phase 1/2
416
Alabama, Florida, Iowa, Missouri, New Jersey, Ohio, Oregon, Pennsylvania
2025-02-04
Recruiting
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
NCT06805825Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma
Novelty Nobility, Inc.
Phase 1
67
Michigan, Ohio, Oregon, Texas, Virginia
2025-02-03
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Massachusetts, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island
2025-01-30
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
NCT06667687Non-Hodgkin's Lymphoma
AbbVie
Phase 1
21
North Carolina, Oregon, Texas, Utah, Virginia
2025-01-16
Active, closed
Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array
NCT06598059Hearing Loss
DrugDexamethasone
Cochlear
Not applicable
56
California, Colorado, Iowa, Michigan, Missouri, New York, Ohio, Oregon
2025-01-03
Active, closed
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
NCT06718101Atopic Dermatitis
DrugLutikizumab
AbbVie
Phase 2
83
Arizona, California, Colorado, Florida, Illinois, Nebraska, New York, Oregon
2024-12-19
Recruiting
Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
NCT06394830Interstitial Cystitis, Bladder Pain Syndrome
DrugVNX001
Vaneltix Pharma, Inc.
Phase 2
50
Arizona, California, Georgia, Oregon
2024-12-13
Recruiting
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
NCT06463028Endometrial Cancer
DrugsSerabelisib·Sapanisertib·Paclitaxel
Faeth Therapeutics
Phase 2
40
California, Florida, Maryland, Minnesota, New York, Ohio, Oregon, Pennsylvania
2024-12-12
Active, closed
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06627179Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
Laboratoires Thea
Phase 2
81
California, Florida, Georgia, Massachusetts, Michigan, Oregon, Pennsylvania, Texas
2024-12-11
Recruiting
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
NCT06454188Psoriatic Arthritis, Spondyloarthritis, Axial
DrugUpadacitinib
CARE ARTHRITIS LTD.
Phase 4
100
Ohio, Oregon, Pennsylvania
2024-12-03
Active, closed
Retrospective Acute Care Appendectomy Study
NCT06624215Acute Appendicitis
Intuitive Surgical
Observational
1,000
Ohio, Oregon, Texas
2024-11-22
Active, closed
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
NCT06465329Non-Small Cell Lung Cancer
DrugsMarlotamig·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
120
California, Illinois, Michigan, Ohio, Oregon, Rhode Island, South Dakota, Tennessee
2024-11-18
Recruiting
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
NCT06422923Epilepsy, Temporal Lobe
DrugNRTX-1001
Neurona Therapeutics
Phase 1/2
10
Arkansas, California, Colorado, Illinois, Iowa, New York, North Carolina, Oregon
2024-11-14
Active, closed
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501Chronic Lymphocytic Leukemia
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
94
Florida, Georgia, Illinois, Maryland, Nebraska, Oregon, Texas, Utah
2024-11-14
Active, closed
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
NCT06625177Vitiligo
DrugTEV-53408
Teva Branded Pharmaceutical Products R&D LLC
Phase 1
66
Arizona, Arkansas, California, Florida, Illinois, Kentucky, Michigan, Oregon
2024-11-11
Recruiting
Evaluation of Gixam's Performance in a FIT Negative Population
NCT06612281Colorectal Adenoma, Colorectal Cancer (CRC), Colorectal Cancer (CRC) Screening
Jubaan Ltd.
Phase 2
400
Oregon
2024-11-01
Recruiting
Post-Market Clinical Investigation of the IotaSOFT Insertion System
NCT06664697Hearing Loss, Cochlear, Cochlear Implantation, Hearing Loss, Sensorineural
iotaMotion, Inc.
Observational
50
Indiana, Iowa, Oregon
2024-10-01
Active, closed
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
NCT06555796Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
DrugXaluritamig
Amgen
Phase 1
50
Minnesota, New York, North Carolina, Oregon, Pennsylvania, Texas, Washington
2024-09-23
Recruiting
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
NCT06370182Acute Ischemic Stroke From Large Vessel Occlusion
Anaconda Biomed S.L.
Not applicable
327
Florida, Georgia, Illinois, Iowa, Massachusetts, New York, Oregon, Pennsylvania
2024-09-09
Recruiting
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
NCT06193889Myasthenia Gravis, Generalized Myasthenia Gravis
DrugsKYV-101·Fludarabine·Cyclophosphamide
Kyverna Therapeutics
Phase 2/3
66
California, Florida, Indiana, Missouri, Oregon, Pennsylvania, Texas, Utah
2024-08-28
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
California, Maryland, New York, North Carolina, Ohio, Oregon, Pennsylvania, Texas
2024-08-19
Active, closed
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
NCT05589896Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
Ossium Health, Inc.
Phase 1/2
12
California, Florida, Georgia, Michigan, Oregon, Tennessee, Texas, Utah
2024-08-16
Active, closed
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
Circle Pharma
Phase 1
220
Florida, Massachusetts, Michigan, Nevada, Ohio, Oregon, Tennessee, Texas
2024-08-14
Active, closed
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
NCT06313593Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
37
Alabama, California, Florida, Illinois, Kansas, Michigan, New York, Oregon
2024-08-08
Recruiting
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
NCT06072430Septic Shock, Sepsis, Hypovolemia
Vivacelle Bio
Phase 3
46
Arizona, Georgia, Missouri, Nebraska, North Carolina, Oregon
2024-08-06
Recruiting
SW-682 in Advanced Solid Tumors
NCT06251310Advanced Solid Tumor, Mesothelioma, Malignant
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 1
186
Arizona, California, Ohio, Oregon, Texas
2024-07-31
Recruiting
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
NCT06520345Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Docetaxel
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
520
California, Florida, Maryland, Nebraska, New York, Ohio, Oregon, Utah
2024-07-26
Recruiting
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
NCT06560307Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
Enterra Medical, Inc.
Not applicable
50
Florida, Kentucky, Michigan, Missouri, Oregon, Washington
2024-07-25
Active, closed
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441Resectable Non-small Cell Lung Cancer
DrugsFianlimab·Cemiplimab·Paraplatin·Taxol
Regeneron Pharmaceuticals
Phase 2
195
Florida, Illinois, Kansas, Michigan, Missouri, New York, Oregon, Virginia
2024-07-16
Recruiting
Galleri® in the Medicare Population.
NCT05673018Cancer
GRAIL, Inc.
Not applicable
50,000
Arkansas, California, Florida, Georgia, Indiana, Louisiana, Missouri, Oregon
2024-07-12
Recruiting
Lumason® Infusion vs. Bolus Administrations
NCT06400004Heart Diseases
Bracco Diagnostics, Inc
Phase 3
106
California, Georgia, Massachusetts, Oregon, Texas
2024-07-10
Active, closed
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
NCT06248619Thyroid Eye Disease
DrugTeprotumumab
Amgen
Phase 3
89
Arizona, Illinois, Michigan, Nevada, New Jersey, Oregon, Pennsylvania, Tennessee
2024-07-05
Active, closed
Validation of i-ROP DL to Detect More Than Mild ROP
NCT06109285Retinopathy of Prematurity, ROP
Siloam Vision
Not applicable
16
Oregon
2024-06-25
Recruiting
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT07491172Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder
CRISPR Therapeutics AG
Phase 1
90
Florida, New York, North Carolina, Oregon
2024-06-21
Recruiting
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
NCT06257693Prostate Adenocarcinoma
DrugEnzalutamide
Alessa Therapeutics Inc.
Phase 1
45
California, Illinois, Louisiana, Maryland, Oregon, South Carolina, Virginia, Wisconsin
2024-06-21
Recruiting
Evaluation of the Patellar LIFT System for Subjects With Patellofemoral Cartilage Degeneration
NCT06423300Patellofemoral Osteoarthritis
ZKR Orthopedics Inc
Not applicable
245
California, New York, Ohio, Oregon
2024-06-19
Recruiting
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
NCT06467344Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Ascidian Therapeutics, Inc
Phase 1/2
15
California, Florida, Maryland, Massachusetts, Michigan, Ohio, Oregon, Texas
2024-06-11
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682Atopic Dermatitis
DrugTralokinumab
LEO Pharma
Phase 3
195
Alabama, Arkansas, California, Florida, Georgia, Michigan, Oklahoma, Oregon
2024-06-10
Recruiting
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
NCT06343311B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma
Estrella Immunopharma, Inc.
Phase 1/2
27
California, Ohio, Oregon, Texas, Utah
2024-06-01
Active, closed
A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C
NCT05975021Cardiogenic Shock
Windtree Therapeutics
Phase 1/2
20
Massachusetts, Oregon
2024-06-01
Recruiting
Post-Market Clinical Study of Functional Motion Outcomes in Subjects Treated With the Minuteman Device
NCT06355791Degenerative Conditions of the Lumbar Spine, Lumbar Spinal Stenosis, Spondylolisthesis
Spinal Simplicity LLC
Not applicable
150
Georgia, Indiana, Kansas, Minnesota, Oregon, West Virginia
2024-05-29
Recruiting
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
NCT06402201Select Advanced Solid Tumors
CDR-Life AG
Phase 1
42
Florida, Michigan, Oregon, Pennsylvania
2024-05-24
Recruiting
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NCT06414954Myasthenia Gravis, Myasthenia Gravis, MuSK
NMD Pharma A/S
Phase 2
84
California, Colorado, Florida, Georgia, Missouri, North Carolina, Ohio, Oregon
2024-05-16
Recruiting
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
NCT06452316Limbal Stem Cell Deficiency
DrugCSB-001 Ophthalmic
Claris Biotherapeutics, Inc.
Phase 1
75
California, Indiana, Minnesota, Oregon, Texas
2024-05-15
Recruiting
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
NCT05703971Small Cell Lung Cancer Extensive Stage
DrugsQuaratusugene ozeplasmid·Tecentriq·Atezolizumab
Genprex, Inc.
Phase 1/2
62
Colorado, Missouri, Ohio, Oregon, Texas, Virginia, Washington
2024-05-09
Recruiting
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
NCT06138639Duchenne Muscular Dystrophy
Solid Biosciences Inc.
Phase 1/2
60
Arkansas, California, Georgia, Illinois, Missouri, Ohio, Oregon, Pennsylvania
2024-05-06
Active, closed
Blood Purification for the Treatment of Pathogen Associated Shock
NCT05011656Septic Shock
ExThera Medical Corporation
Not applicable
15
District of Columbia, Georgia, Michigan, Minnesota, Oregon, Pennsylvania, Texas
2024-04-19
Active, closed
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
NCT06125951Dementia Moderate, Dementia, Mild, Alzheimer Disease
Actinogen Medical
Phase 2/3
247
California, Colorado, Florida, Georgia, New Jersey, New York, Ohio, Oregon
2024-04-12
Active, closed
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
NCT06255782Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn
iECURE, Inc.
Phase 3
20
California, Colorado, Georgia, Illinois, New York, Oregon
2024-04-08
Recruiting
The HYALEX Pivotal Study
NCT06368700Damaged Chondral or Osteochondral Area
Hyalex Orthopaedics, Inc.
Not applicable
85
California, Louisiana, New York, Oregon
2024-04-04
Recruiting
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
NCT05848284Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
VDyne, Inc.
Not applicable
30
California, Michigan, Minnesota, New York, Ohio, Oregon, South Carolina, Tennessee
2024-04-01
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
NCT06158854Immunoglobulin Light Chain (AL) Amyloidosis
DrugEtentamig
AbbVie
Phase 1/2
76
Florida, Massachusetts, Minnesota, New York, North Carolina, Oregon, Tennessee, Washington
2024-04-01
Active, closed
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
NCT06560476Benign Prostatic Hyperplasia
Urotronic Inc.
Observational
500
Florida, Nebraska, Nevada, New York, Oregon, Texas, Virginia
2024-03-30
Recruiting
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
NCT06093672Polycythemia Vera
DrugHydroxyurea
Italfarmaco
Phase 3
220
Alabama, California, Colorado, Maryland, New York, North Carolina, Ohio, Oregon
2024-03-26
Recruiting
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
AstraZeneca
Phase 1
108
California, Florida, Illinois, Kansas, Massachusetts, Missouri, New York, Oregon
2024-03-22
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
MacroGenics
Phase 1
250
California, Michigan, New York, Oregon, Texas, Utah
2024-03-06
Active, closed
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
Affini-T Therapeutics, Inc.
Phase 1/2
100
California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin
2024-03-06
Recruiting
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
NCT06201416Rheumatoid Arthritis
DrugSBT777101
Sonoma Biotherapeutics, Inc.
Phase 1
48
Arizona, California, Colorado, Illinois, Massachusetts, Oregon
2024-03-06
Recruiting
AETOS Shoulder System
NCT06319911Shoulder Osteoarthritis, Shoulder Arthritis
Smith & Nephew, Inc.
Observational
220
California, Colorado, Georgia, Oregon, Pennsylvania
2024-03-05
Recruiting
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
NCT06234098Solid Tumor
Alyssum Therapeutics
Phase 1/2
100
Arizona, California, New York, Oregon, Texas
2024-02-13
Recruiting
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
NCT06312722Benign Prostatic Hyperplasia
Urotronic Inc.
Not applicable
92
Arkansas, Florida, Louisiana, Nevada, Oregon, Texas
2024-02-07
Recruiting
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
NCT06257355Corneal Scar
DrugCSB-001 Ophthalmic
Claris Biotherapeutics, Inc.
Phase 1
20
California, Indiana, Minnesota, Oregon, Texas, Virginia
2024-02-05
Recruiting
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
NCT06305234Phenylketonuria (PKU)
DrugPegvaliase
BioMarin Pharmaceutical
Observational
200
Colorado, Georgia, Illinois, Indiana, Louisiana, Massachusetts, Oregon, Pennsylvania
2024-01-20
Recruiting
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
NCT06171750Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor
DrugsTolododekin alfa·Cemiplimab
Ankyra Therapeutics, Inc
Phase 1
97
Maryland, Massachusetts, Oregon, Pennsylvania
2024-01-19
Recruiting
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
NCT06130553Advanced Solid Tumors That Are MTAP Deficient
DrugsAZD3470·Dato-DXd
AstraZeneca
Phase 1/2
334
California, Connecticut, Maryland, Oregon, Pennsylvania, Rhode Island, Virginia
2024-01-18
Active, closed
Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children
NCT06285812Otitis Media Acute
PhotoniCare, Inc.
Observational
700
District of Columbia, Florida, New York, Oregon, South Carolina, Tennessee
2024-01-10
Active, closed
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
NCT05849298Prostatic Neoplasm
DrugsARPI·Pylarify·Illuccix·Lu-PSMA
Novartis Pharmaceuticals
Phase 2
49
Colorado, Georgia, Indiana, Iowa, Nebraska, Oregon, Pennsylvania, Texas
2024-01-03
Active, closed
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
NCT05685004Glioblastoma Multiforme of Brain
DrugTemozolomide
TVAX Biomedical
Phase 2/3
120
Arizona, California, Florida, Georgia, Kansas, New Jersey, Oregon
2023-12-27
Active, closed
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
Axonics, Inc.
Not applicable
144
Connecticut, Florida, Georgia, Minnesota, Nebraska, New York, Oregon, South Carolina
2023-12-08
Active, closed
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
NCT06116786Carcinoma, Non-small-Cell Lung
DrugsJNJ-86974680·Cetrelimab
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
67
Georgia, New Jersey, New York, Oregon, Pennsylvania, Virginia
2023-11-27
Active, closed
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837Pulmonary Disease, Chronic Obstructive
DrugGSK3862995B
GlaxoSmithKline
Phase 1
127
Arizona, Florida, Georgia, North Carolina, Oregon, Pennsylvania, South Carolina, Texas
2023-11-27
Recruiting
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943Lymphatic Malformations
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2/3
232
California, District of Columbia, Florida, Massachusetts, Missouri, North Carolina, Ohio, Oregon
2023-11-24
By invitation
A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
NCT06275620X-Linked Retinitis Pigmentosa
DrugAGTC-501
Beacon Therapeutics
Phase 2
24
Florida, Massachusetts, Ohio, Oregon, Texas
2023-11-14
Recruiting
MISHA Post-Market Clinical Study
NCT06118892Osteo Arthritis Knee
Moximed
Not applicable
120
California, North Carolina, Oregon, Virginia
2023-11-03
Recruiting
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
NCT06095089Prostatic Neoplasms
DrugsJNJ-101556143·JNJ-87189401·Lutetium Lu-177 vipivotide tetraxetan·Pasritamig
Janssen Research & Development, LLC
Phase 1
355
Colorado, Georgia, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania
2023-11-01
Recruiting
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NCT06119685NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma
DrugsMesna·Darzalex·Isatuximab·Aldesleukin
Indapta Therapeutics, INC.
Phase 1/2
128
California, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Oregon
2023-10-25
Recruiting
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
NCT05871970Lymphatic Malformation
DrugTARA-002
Protara Therapeutics
Phase 2
38
Alabama, Arkansas, Colorado, District of Columbia, Florida, New York, Ohio, Oregon
2023-10-18
Recruiting
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
NCT06357754Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma
DrugsIdecabtagene vicleucel·Lisocabtagene maraleucel
Bristol-Myers Squibb
Observational
50
Oregon, Texas, Utah, Wisconsin
2023-10-06
Recruiting
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630Juvenile Idiopathic Arthritis
DrugsUpadacitinib·Tocilizumab
AbbVie
Phase 3
90
Arizona, District of Columbia, New York, North Carolina, Ohio, Oregon
2023-10-02
Recruiting
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
NCT05957367GIST
DrugRipretinib
Deciphera Pharmaceuticals, LLC
Phase 1/2
94
California, Florida, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon
2023-09-28
Recruiting
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT05981703Advanced Solid Tumor, Solid Tumor
DrugTislelizumab
BeOne Medicines
Phase 1
337
California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas
2023-09-21
Recruiting
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
NCT06193928Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
DrugsLivmarli·Maralixibat
Mirum Pharmaceuticals, Inc.
Observational
70
California, Colorado, Georgia, Missouri, Oregon, Pennsylvania, Utah
2023-09-21
Active, closed
A Study of AT-02 in Subjects With Systemic Amyloidosis.
NCT05951049Amyloidosis; Systemic
Attralus, Inc.
Phase 2
120
Kansas, Ohio, Oregon, Pennsylvania
2023-09-21
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)
DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone
Regeneron Pharmaceuticals
Phase 3
410
California, Florida, Kentucky, New York, North Carolina, Oregon, Texas, Washington
2023-09-18
By invitation
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
NCT05962398Hemophilia B
CSL Behring
Observational
56
Arizona, Arkansas, California, Colorado, Florida, Michigan, North Carolina, Oregon
2023-08-30
Recruiting
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT05867251Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
DrugsAVZO-021·Sacituzumab Govitecan·Abemaciclib·Ribociclib
Avenzo Therapeutics, Inc.
Phase 1/2
430
Connecticut, Florida, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Texas
2023-08-30
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Florida, Georgia, Kansas, Michigan, New Jersey, New York, Oregon, Rhode Island
2023-08-18
Active, closed
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304Advanced or Metastatic Solid Tumors
DrugsNaporafenib·Trametinib
Erasca, Inc.
Phase 1
86
California, Connecticut, Florida, Georgia, Michigan, Missouri, Nevada, Oregon
2023-08-17
Active, closed
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
NCT05771480Biliary Tract Cancer
DrugsAlbumin-Bound Paclitaxel·Teysuno·Durvalumab·Oxaliplatin
AstraZeneca
Phase 3
142
Alabama, California, District of Columbia, Oregon
2023-08-16
Recruiting
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
NCT05836259Hypertrophic Cardiomyopathy
Tenaya Therapeutics
Phase 1/2
30
California, Georgia, Massachusetts, Minnesota, Ohio, Oregon, Pennsylvania, Texas
2023-08-10
Active, closed
4D-150 in Patients With Diabetic Macular Edema
NCT05930561Diabetic Macular Edema, Diabetic Retinopathy
DrugsAflibercept IVT·4D-150 IVT·Eylea
4D Molecular Therapeutics
Phase 2
72
Maryland, Oregon, Pennsylvania, Texas, Virginia
2023-08-09
Active, closed
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593Geographic Atrophy
DrugTinlarebant
Belite Bio, Inc
Phase 3
429
Arizona, California, Florida, Maryland, Minnesota, New York, North Carolina, Oregon
2023-07-27
Active, closed
Cemented vs Cementless Persona Keel RCT
NCT05630053Knee Pain Chronic, Rheumatoid Arthritis, Osteoarthritis, Traumatic Arthritis
Zimmer Biomet
Not applicable
300
Colorado, Illinois, Maryland, Oregon, Pennsylvania, Virginia
2023-07-25
Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma
AstraZeneca
Phase 1
45
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Oregon
2023-07-12
Active, closed
Vibrotactile Coordinated Reset: A Non-invasive Treatment for Parkinson's Disease 2
NCT05881460Parkinson Disease
Synergic Medical Technologies, Inc.
Not applicable
30
Oregon
2023-07-12
Recruiting
NIBP Validation Study
NCT05673408Critical Illness
Philips Clinical & Medical Affairs Global
Observational
189
Florida, North Carolina, Oregon, Texas, Utah
2023-06-23
Active, closed
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
NCT06087458Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration
DrugVOY-101
Perceive Biotherapeutics, Inc.
Phase 1/2
60
Arizona, California, Massachusetts, Missouri, New Jersey, Oregon, South Dakota, Texas
2023-06-21
Recruiting
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
NCT05780034Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology Inc
Phase 1
60
Colorado, Florida, North Carolina, Ohio, Oregon, Tennessee, Texas, Washington
2023-06-20
Active, closed
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
NCT05902520HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer
DrugAldesleukin
AgonOx, Inc.
Phase 1
18
Oregon
2023-06-19
Recruiting
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
NCT05865535Cachexia
AVEO Pharmaceuticals, Inc.
Phase 1
30
California, Connecticut, Florida, Nebraska, New Jersey, New York, Oregon, South Carolina
2023-06-13
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
California, Colorado, Kentucky, Massachusetts, Michigan, Ohio, Oregon, Rhode Island
2023-06-05
Recruiting
Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression
NCT06017622Acute Cannabis-induced CNS Depression
Anebulo Pharmaceuticals
Observational
36
Massachusetts, Ohio, Oregon
2023-06-01
Active, closed
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
NCT05885464Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
Beam Therapeutics Inc.
Phase 1/2
5
California, Colorado, Illinois, Kansas, Massachusetts, Ohio, Oregon, Pennsylvania
2023-05-25
Active, closed
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT05908734Carcinoma, Non-Small-Cell Lung
DrugsCetrelimab·Amivantamab
Janssen Research & Development, LLC
Phase 1/2
71
California, Oregon, Texas, Virginia
2023-05-18
Active, closed
Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy
NCT05777317Painful Diabetic Neuropathy
Nevro Corp
Not applicable
143
North Carolina, Oregon
2023-04-24
Active, closed
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
NCT05539430Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
Legend Biotech USA Inc
Phase 1
56
Florida, Michigan, New Jersey, New York, North Carolina, Oregon, Tennessee, Washington
2023-04-18
Active, closed
Promising ROd-cone DYstrophy Gene therapY
NCT05748873Retinitis Pigmentosa
SparingVision
Phase 1/2
33
Florida, Massachusetts, Oregon, Pennsylvania, Texas
2023-04-12
Active, closed
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
NCT05686317Heart Failure
Edwards Lifesciences
Not applicable
100
California, Illinois, Kansas, Minnesota, New York, Ohio, Oklahoma, Oregon
2023-04-01
By invitation
G7 Dual Mobility With Vivacit-E or Longevity PMCF
NCT05548972Hip Osteoarthritis, Rheumatoid Arthritis, Joint Diseases, Avascular Necrosis
Zimmer Biomet
Not applicable
358
Arkansas, Colorado, New Jersey, New York, Ohio, Oregon
2023-03-20
Active, closed
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan·Nab-paclitaxel
Gilead Sciences
Phase 2
192
Arizona, Indiana, Kentucky, Missouri, Ohio, Oregon
2023-03-16
Active, closed
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
NCT05662397Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
DrugCemiplimab
HotSpot Therapeutics, Inc
Phase 1/2
77
Florida, Nevada, New York, Oregon, Pennsylvania, Texas
2023-03-15
Active, closed
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
NCT05635708Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
DrugsGimistotug·Alcestobart·Nab-paclitaxel·Pemetrexed
BeiGene
Phase 2
400
California, Massachusetts, New York, Oregon, Texas
2023-03-07
Active, closed
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
NCT05698329Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
AiViva BioPharma, Inc.
Phase 1
19
California, Oregon, Texas
2023-03-02
Active, closed
Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease
NCT05830110Parkinson's Disease
Synergic Medical Technologies, Inc.
Not applicable
30
Oregon
2023-03-01
Active, closed
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
NCT05201066Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
DrugsSpartalizumab·Decitabine·Azacitidine·Venetoclax
Novartis Pharmaceuticals
Phase 2
33
Oregon, Utah
2023-02-28
Active, closed
A Prospective Cohort Post Market Registry Evaluating Outcomes of Bridge-Enhanced ACL Restoration (BEAR®)
NCT05398341Anterior Cruciate Ligament Injuries
Miach Orthopaedics
Observational
300
California, Colorado, Florida, New Jersey, New York, North Carolina, Oregon
2023-02-28
Recruiting
Home Sleep Therapy for Older Adults With MCI
NCT05771844Mild Cognitive Impairment, Sleep, Transcranial Electrical Stimulation, Machine Learning
Brain Electrophysiology Laboratory Company
Not applicable
60
North Carolina, Oregon
2023-02-08
Active, closed
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
NCT05731271Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
111
Oregon, Texas
2023-02-08
Active, closed
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
NCT05797896Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration
Complement Therapeutics
Observational
250
California, Indiana, Maryland, Nevada, Oregon, Pennsylvania, Texas
2023-02-07
Recruiting
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
NCT05768932Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
SillaJen, Inc.
Phase 1
260
Connecticut, Florida, Georgia, Michigan, New York, Oregon, Texas
2022-12-14
Active, closed
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988Non-small Cell Lung Cancer
DrugsSunvozertinib·Pemetrexed·Carboplatin
Dizal Pharmaceuticals
Phase 3
324
California, Colorado, Florida, New York, Ohio, Oregon, Texas, Virginia
2022-12-13
Active, closed
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
Immunitas Therapeutics
Phase 1/2
67
Arizona, Colorado, Florida, Oklahoma, Oregon, Tennessee, Texas, Virginia
2022-11-28
Active, closed
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
DrugsAsciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
568
Colorado, Illinois, Minnesota, North Carolina, Ohio, Oregon, Texas, Virginia
2022-11-21
Active, closed
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
NCT05546580Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
DrugsXospata·Gilteritinib
Oryzon Genomics S.A.
Phase 1
50
Arizona, Florida, Maryland, Massachusetts, New Jersey, New York, North Carolina, Oregon
2022-11-14
Active, closed
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204Non-Small Cell Lung Cancer
DrugsEntrectinib·Alectinib·Durvalumab
Hoffmann-La Roche
Phase 3
68
Oregon, Pennsylvania
2022-11-01
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
California, District of Columbia, Florida, Illinois, North Carolina, Ohio, Oregon, Pennsylvania
2022-10-12
Active, closed
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugPIT565
Novartis Pharmaceuticals
Phase 1
61
Florida, Illinois, Kansas, New York, Oregon
2022-10-03
Recruiting
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
NCT05422911Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer
DrugsZytiga·Apalutamide·Xtandi·Abiraterone acetate
Sun Pharmaceutical Industries Limited
Phase 2
192
California, Florida, Michigan, Missouri, New York, North Carolina, Oregon, Pennsylvania
2022-08-31
Recruiting
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms
DrugsElacestrant·Abemaciclib
Stemline Therapeutics, Inc.
Phase 1/2
73
California, Illinois, Massachusetts, Michigan, Ohio, Oregon, Tennessee, Texas
2022-08-31
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Michigan, New York, Oregon, Texas, Wisconsin
2022-08-30
Active, closed
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
NCT05524883Duchenne Muscular Dystrophy (DMD)
DrugZeleciment Rostudirsen
Dyne Therapeutics
Phase 1/2
86
California, Colorado, Georgia, Massachusetts, Ohio, Oregon, Pennsylvania, Utah
2022-08-12
Recruiting
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
NCT05317858Brain Tumor, Non Small Cell Lung Cancer
DrugsCemiplimab·Tecentriq·Atezolizumab·Nivolumab
InSightec
Phase 3
30
Arizona, California, Florida, Maryland, North Carolina, Oregon, Rhode Island, Virginia
2022-08-12
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 3
418
California, Colorado, Florida, Kansas, Michigan, New Jersey, New York, Oregon
2022-08-05
Active, closed
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
NCT05180799NSCLC, Melanoma
DrugsPemetrexed·Nivolumab·Pembrolizumab
BioAtla, Inc.
Phase 1/2
320
California, Georgia, Indiana, New Jersey, New York, Ohio, Oregon, Utah
2022-08-03
Active, closed
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
DrugIDRX-42
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase 1
276
Florida, Illinois, Massachusetts, Missouri, New York, Oregon, Pennsylvania, Texas
2022-08-03
Active, closed
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
NCT05573984Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod
PYC Therapeutics
Observational
50
California, Florida, Michigan, Oregon, Texas
2022-07-07
Active, closed
PDN Post Market, Multicenter, Prospective, Global Clinical Study
NCT05301816Diabetic Neuropathy, Painful
Nevro Corp
Not applicable
497
Alaska, Michigan, Ohio, Oklahoma, Oregon, Pennsylvania, Virginia
2022-07-05
Recruiting
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT05417594Advanced Solid Malignancies
DrugsPalacaparib·Dato-DXd·Trastuzumab deruxtecan·Temozolomide
AstraZeneca
Phase 1/2
695
California, Illinois, Massachusetts, New York, Oregon, Texas, Virginia
2022-06-24
Recruiting
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
NCT05813678Phenylketonuria (PKU)
DrugPegvaliase
BioMarin Pharmaceutical
Observational
450
Colorado, Georgia, Illinois, Indiana, Louisiana, Massachusetts, Oregon, Pennsylvania
2022-06-06
Recruiting
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
DrugELVN-001
Enliven Therapeutics
Phase 1
250
New York, Oregon, Texas
2022-05-22
Active, closed
A.L.P.S. Clavicle Plating System PMCF
NCT05327959Clavicle Fracture, Clavicle Injury
Zimmer Biomet
Not applicable
98
Florida, Michigan, Oregon, Texas
2022-05-13
Recruiting
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
Adela, Inc
Observational
7,000
California, Florida, Georgia, Indiana, Kentucky, Minnesota, Ohio, Oregon
2022-05-03
Active, closed
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
NCT05196035Chronic Kidney Disease, Proteinuria
DrugFinerenone
Bayer
Phase 3
219
California, Florida, Maryland, Missouri, Ohio, Oregon, Utah, Washington
2022-03-28
Recruiting
GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
NCT04864054Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm, Metastatic Liver Cancer
Eureka Therapeutics Inc.
Phase 1/2
60
California, Kansas, New York, Oregon, Texas, Washington
2022-03-11
Active, closed
Cardiac Implantable Electronic Device (CIED) Research Study
NCT05061862Arrhythmias, Cardiac, Bradycardia, Tachycardia
Medtronic Cardiac Rhythm and Heart Failure
Observational
1,000
Florida, Georgia, Oregon, Pennsylvania, Virginia
2022-03-06
Active, closed
Clinical Study Of a Micro-Implantable Pulse Generator For The Treatment of Peripheral Neuropathic Pain
NCT05287373Peripheral Neuralgia, Chronic Pain
Nalu Medical, Inc.
Not applicable
89
Arizona, Arkansas, California, Colorado, District of Columbia, North Carolina, Oregon, Texas
2022-02-23
Active, closed
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
NCT05203939Retinitis Pigmentosa, Leber Congenital Amaurosis
Ocugen
Phase 1/2
22
Arizona, California, Florida, Georgia, Oregon, Pennsylvania, Texas
2022-01-24
Active, closed
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
NCT05071300Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
DrugEplontersen
Ionis Pharmaceuticals, Inc.
Phase 3
151
Arizona, Indiana, Maryland, Massachusetts, New York, North Carolina, Oregon, Washington
2022-01-04
Active, closed
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
NCT05199272Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer
23andMe, Inc.
Phase 1/2
141
California, Georgia, Michigan, New York, Oregon, Tennessee, Texas, Virginia
2021-12-29
Active, closed
A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis
NCT05197036Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
Smith & Nephew, Inc.
Observational
299
Georgia, Massachusetts, Michigan, New York, North Carolina, Oregon, South Carolina, Tennessee
2021-12-21
Active, closed
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
NCT04999969Locally Advanced or Metastatic Solid Tumours
DrugsAZD0171·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 2
126
California, Georgia, Idaho, Massachusetts, Michigan, New York, Oregon, Texas
2021-12-10
Active, closed
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
NCT05172726Plaque Psoriasis
DrugTapinarof
Organon and Co
Phase 3
58
Arkansas, California, Florida, Illinois, Indiana, Ohio, Oregon, Washington
2021-12-02
Active, closed
Pyrocarbon Clinical Follow-up Study
NCT05049993Osteoarthritis of the Shoulder, Avascular Necrosis, Traumatic Arthritis
Stryker Trauma and Extremities
Observational
76
Colorado, Florida, Louisiana, Maryland, Minnesota, Missouri, North Carolina, Oregon
2021-10-27
Recruiting
ConsideRAte Study - Splenic Stimulation for RA
NCT05003310Rheumatoid Arthritis
DrugBaricitinib
Galvani Bioelectronics
Not applicable
28
Alabama, California, Maryland, New York, Oregon, Pennsylvania, Texas
2021-10-19
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine
AstraZeneca
Phase 3
732
California, Florida, Georgia, Massachusetts, Michigan, New York, Ohio, Oregon
2021-10-18
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Colorado, Florida, Kentucky, Massachusetts, North Carolina, Oregon, South Dakota, Tennessee
2021-10-06
Active, closed
Avenir Complete Post-Market Clinical Follow-Up Study
NCT04731077Osteoarthritis, Hip, Avascular Necrosis of Hip, Avascular Necrosis of the Femoral Head, Post-traumatic; Arthrosis
Zimmer Biomet
Not applicable
275
Mississippi, Missouri, Oregon
2021-09-27
Active, closed
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
NCT04909801Rheumatoid Arthritis
DrugsAbatacept·Humira·Adalimumab·Methotrexate
Bristol-Myers Squibb
Phase 3
338
California, Colorado, Maryland, Minnesota, New Jersey, New York, North Carolina, Oregon
2021-09-15
Active, closed
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT04782687Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell
DrugsDarzalex·Selinexor·Daratumumab·Lenalidomide
US Oncology Research
Phase 2
73
Arizona, Colorado, Maryland, New York, Oregon, Texas, Virginia
2021-09-10
Active, closed
REFLECTION: A Clinical Practice Learning Program for Galleri®
NCT05205967Early Detection of Cancer, Cancer
GRAIL, Inc.
Observational
14,633
Arizona, California, Florida, Louisiana, Massachusetts, Oregon, Pennsylvania, South Carolina
2021-08-23
Active, closed
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
NCT04691154Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
Liquidia Technologies, Inc.
Phase 3
28
Arizona, California, Florida, New York, Ohio, Oregon, Texas
2021-08-01
Active, closed
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
NCT04541108Solid Tumor
DrugsAZD9592·Sabestomig·Volrustomig·Rilvegostomig
Presage Biosciences
Phase EARLY_PHASE1
15
Louisiana, New York, North Carolina, Ohio, Oregon, Pennsylvania, South Carolina, Washington
2021-07-26
Active, closed
G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
NCT04754087Total Hip Arthroplasty, Degenerative Joint Disease of Hip, Avascular Necrosis of Hip, Rheumatoid Arthritis of Hip
Zimmer Biomet
Not applicable
300
Colorado, Indiana, North Carolina, Oregon, Utah
2021-07-07
Active, closed
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
NCT04635384Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
CareDx
Observational
307
California, Florida, Georgia, Massachusetts, Missouri, New York, Ohio, Oregon
2021-06-30
Recruiting
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
DrugsImzokitug·Pumitamig·Docetaxel·Nivolumab
Bristol-Myers Squibb
Phase 1/2
1,109
California, Iowa, New Jersey, New York, Oregon, Tennessee, Texas
2021-05-27
Active, closed
A Clinical Study on Implants With TiUltra Technology and Associated Prosthetic Components
NCT04737421Marginal Bone Level Change
Nobel Biocare
Observational
1,000
Alabama, Illinois, New York, Oregon
2021-05-26
Active, closed
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
NCT04675333Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
DrugsEvorpacept·Cisplatin/Carboplatin·Fluorouracil·Keytruda
ALX Oncology Inc.
Phase 2
172
California, Florida, Illinois, Kentucky, Maryland, New York, Ohio, Oregon
2021-05-10
Active, closed
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
NCT04475926Limb-girdle Muscular Dystrophy
Sarepta Therapeutics, Inc.
Observational
205
Arizona, Arkansas, California, Illinois, Ohio, Oregon, Pennsylvania, Texas
2021-04-22
Active, closed
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
NCT06333249X-Linked Retinitis Pigmentosa
DrugRAAV2tYF-GRK1-RPGR
Beacon Therapeutics
Phase 2
14
Florida, Massachusetts, Ohio, Oregon, Texas
2021-04-13
Active, closed
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT04696731Advanced/Metastatic Clear Cell Renal Cell Carcinoma
DrugsALLO-647·Fludarabine·Cyclophosphamide
Allogene Therapeutics
Phase 1
120
California, Connecticut, District of Columbia, Florida, Michigan, New York, Oregon, Texas
2021-02-24
Active, closed
INFINITY™ With ADAPTIS™ Technology Study
NCT04594993Arthritis, Rheumatoid
Stryker Trauma and Extremities
Observational
200
Arizona, California, Colorado, Florida, Illinois, New York, Oregon, South Carolina
2021-02-09
Recruiting
OssiMend BA in Posterolateral Instrumented Lumbar Fusion
NCT04775537Spinal Disease, Degenerative Disc Disease
Collagen Matrix
Observational
120
California, Connecticut, New Jersey, Oregon
2021-01-21
Active, closed
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
NCT04305795Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
DrugsCemiplimab·Pembrolizumab
Rakuten Medical, Inc.
Phase 1/2
23
Florida, Kentucky, Minnesota, Oregon, Pennsylvania, Tennessee, Texas
2020-12-21
Active, closed
Beating Heart Mitral Valve Repair With the HARPOON™ System
NCT04375332Mitral Regurgitation
Edwards Lifesciences
Not applicable
25
California, Georgia, Maryland, Michigan, Minnesota, Oregon, Tennessee, Utah
2020-12-16
Active, closed
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
NCT04471727Small-Cell Lung Cancer, Neuroendocrine Carcinoma
DrugsGocatamig·Ifinatamab Deruxtecan·Atezolizumab
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2
232
California, Colorado, Massachusetts, Michigan, New York, Ohio, Oregon, Tennessee
2020-12-14
Recruiting
The Half Moon Transcatheter Mitral Valve Repair (TMVr) Pilot Study
NCT04343313Mitral Valve Insufficiency
Half Moon Medical
Not applicable
30
New York, Ohio, Oregon, Pennsylvania
2020-12-08
Active, closed
Triac Trial II in MCT8 Deficiency Patients
NCT02396459Allan-Herndon-Dudley Syndrome
Rare Thyroid Therapeutics International AB
Phase 2
22
Oregon, Pennsylvania
2020-12-07
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
NCT04576455Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Fulvestrant
Hoffmann-La Roche
Phase 2
303
Georgia, Ohio, Oregon
2020-11-27
Active, closed
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
NCT04454658Myelofibrosis (MF)
DrugsNavitoclax·Ruxolitinib
AbbVie
Phase 1
21
California, New Hampshire, New York, Ohio, Oklahoma, Oregon, Texas, Washington
2020-11-11
Active, closed
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
NCT04606381Neoplasms
Janssen Research & Development, LLC
Phase 1
158
California, Indiana, New York, Oregon, Tennessee
2020-11-10
Active, closed
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
NCT04524871Advanced Liver Cancers
DrugsADG126·Tobemstomig·Tiragolumab·Tocilizumab
Hoffmann-La Roche
Phase 1/2
518
California, Colorado, Connecticut, District of Columbia, Kentucky, Oregon, Tennessee, Texas
2020-11-01
Active, closed
Study to Evaluate D-1553 in Subjects With Solid Tumors
NCT04585035Solid Tumor, Adult, NSCLC, CRC
DrugD-1553
InventisBio Co., Ltd
Phase 1/2
180
California, Kentucky, Michigan, New York, Oregon
2020-10-02
Active, closed
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
NCT04093349Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, Glycogen Storage Disease Type II
Spark Therapeutics, Inc.
Phase 1/2
4
Arizona, California, Georgia, Kansas, Minnesota, Oregon, Pennsylvania, Utah
2020-10-01
Active, closed
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
DrugsLoncastuximab Tesirine·Rituximab·Oxaliplatin·Gemcitabine
ADC Therapeutics S.A.
Phase 3
440
California, Florida, Iowa, Kentucky, Nevada, Oregon, South Carolina, Virginia
2020-09-16
Active, closed
Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication
NCT042525731 Paravisceral Abdominal Aortic Aneurysm, 2 Juxtarenal Abdominal Aortic Aneurysm, 3 Pararenal Abdominal Aortic Aneurysm, 4 Complex Abdominal Aortic Aneurysms
Endologix
Not applicable
13
Alabama, District of Columbia, Georgia, Indiana, Missouri, New Jersey, New York, Oregon
2020-06-29
Active, closed
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
NCT04517149X-Linked Retinitis Pigmentosa
4D Molecular Therapeutics
Phase 1/2
21
Colorado, Florida, Michigan, New York, North Carolina, Oregon, Texas, Utah
2020-06-09
Active, closed
2019-06 TRISCEND Study
NCT04221490Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Edwards Lifesciences
Not applicable
228
California, Georgia, Illinois, Massachusetts, Michigan, New York, Oregon, Pennsylvania
2020-05-06
Active, closed
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
NCT04184050Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1
100
Arizona, California, Kansas, New York, Oregon, Washington
2020-04-13
Active, closed
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210Multiple Myeloma
DrugsBelantamab mafodotin·Dexamethasone
GlaxoSmithKline
Phase 3
325
Arizona, Colorado, Michigan, Nebraska, New York, Ohio, Oregon, Texas
2020-04-02
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
DrugSacituzumab tirumotecan
Klus Pharma Inc.
Phase 1/2
1,410
California, Florida, Michigan, Oklahoma, Oregon, Texas, Virginia
2020-02-28
By invitation
Survivorship and Effectiveness of the Ortho Development® Entrada™ Hip System for Total Hip Arthroplasty
NCT04277416Total Hip Replacement, Total Hip Arthroplasty
Ortho Development Corporation
Observational
250
Oregon
2020-02-28
Active, closed
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
NCT04146051Myasthenia Gravis, Generalized
DrugDescartes-08
Cartesian Therapeutics
Phase 2
30
California, Colorado, Florida, Georgia, Kansas, New York, North Carolina, Oregon
2019-12-04
By invitation
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
NCT04145375mCRPC
DrugsZEN003694·Xtandi·Enzalutamide
Zenith Epigenetics
Phase 1/2
40
California, Oregon
2019-11-12
Active, closed
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
DrugZipalertinib
Cullinan Therapeutics Inc.
Phase 1/2
284
California, Florida, Massachusetts, Michigan, New Jersey, New York, Ohio, Oregon
2019-10-31
Active, closed
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
NCT04058756Advanced Solid Tumors
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
120
New York, Oregon, Texas
2019-10-30
Active, closed
Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
NCT03920007Leber Congenital Amaurosis, LCA, LCA1
DrugsPrednisolone·Prednisone
Atsena Therapeutics Inc.
Phase 1/2
15
Oregon, Pennsylvania
2019-10-22
Active, closed
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
NCT04123626Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies
ProQR Therapeutics
Phase 1/2
11
Colorado, Florida, Kentucky, Oregon, Texas
2019-10-07
Active, closed
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT04077463Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 1
701
California, Florida, Massachusetts, Michigan, Missouri, New York, Oregon, Pennsylvania
2019-09-04
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
DrugsBendamustine·Zanubrutinib·Rituximab
BeOne Medicines
Phase 3
510
California, Illinois, Massachusetts, Michigan, Nevada, New York, Oregon, Pennsylvania
2019-08-20
Active, closed
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030Metastatic Colorectal Cancer
DrugsFluorouracil·Leucovorin·Ipilimumab·Cetuximab
Bristol-Myers Squibb
Phase 3
839
California, Colorado, Illinois, New York, Oregon, Pennsylvania, Texas, Virginia
2019-08-05
Active, closed
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
NCT03944772Non-Small Cell Lung Cancer
DrugsNecitumumab·Gefitinib·Savolitinib·Selpercatinib
AstraZeneca
Phase 2
247
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New York, Oregon
2019-06-25
Active, closed
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
NCT03725007Juvenile Idiopathic Arthritis (JIA)
DrugUpadacitinib
AbbVie
Phase 1
124
Illinois, Kentucky, Massachusetts, Ohio, Oregon, Pennsylvania, Washington
2019-06-24
Active, closed
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
NCT03872947Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
DrugsTRK-950·Imiquimod·Ramucirumab·Leucovorin
Toray Industries, Inc
Phase 1
138
Arizona, California, Louisiana, New Jersey, New York, Oregon, Texas, Virginia
2019-04-26
Active, closed
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
NCT03941379Choroidal Melanoma, Indeterminate Lesions of Eye
Aura Biosciences
Observational
63
Arizona, California, Massachusetts, Michigan, Minnesota, New York, Oregon, Pennsylvania
2019-03-27
Active, closed
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT03860272Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
DrugsBalstilimab·Botensilimab
Agenus Inc.
Phase 1
499
Arizona, California, Colorado, Connecticut, Florida, Massachusetts, New York, Oregon
2019-03-20
Active, closed
Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer
NCT03621644Pancreatic Cancer
Viewray Inc.
Not applicable
133
California, Florida, Massachusetts, Michigan, Missouri, New Hampshire, New York, Oregon
2019-01-01
Active, closed
Post-Authorization Long-Term Safety Study of LUTATHERA
NCT03691064Neuroendocrine Tumors
DrugLutathera
Advanced Accelerator Applications
Observational
1,014
Arizona, Ohio, Oregon, Washington
2018-11-28
Active, closed
Venous Sinus Stenting With the River Stent in IIH
NCT03556085Idiopathic Intracranial Hypertension
Serenity Medical, Inc.
Not applicable
39
Florida, New York, North Carolina, Oregon
2018-08-24
Active, closed
Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A
NCT03432520Hemophilia A
Spark Therapeutics, Inc.
Observational
29
Massachusetts, Mississippi, Missouri, Oregon, Pennsylvania, Virginia
2018-08-14
Active, closed
Open-Label Study of AG10 in Patients with Cardiomyopathy
NCT03536767Amyloid Cardiomyopathy
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 2
55
California, Connecticut, Illinois, Massachusetts, Minnesota, New York, Oregon, South Carolina
2018-08-08
Recruiting
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
NCT03592472Renal Cell Carcinoma
DrugsAbexinostat·Pazopanib
Xynomic Pharmaceuticals, Inc.
Phase 3
413
Arizona, California, Kentucky, Louisiana, Nebraska, New York, Ohio, Oregon
2018-07-17
Active, closed
Clinical Study of Edwards Cardioband FIT Valve Repair System
NCT03382457Tricuspid Regurgitation
Edwards Lifesciences
Not applicable
75
Illinois, Minnesota, New Jersey, New York, Oregon, Pennsylvania, Texas, Utah
2018-07-01
Active, closed
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
NCT03316560X-Linked Retinitis Pigmentosa
DrugRAAV2tYF-GRK1-RPGR
Beacon Therapeutics
Phase 1/2
29
North Carolina, Ohio, Oregon, Texas
2018-04-16
By invitation
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
NCT03391778Neoplasms
USWM CT, LLC
Phase 1
250
Georgia, Maryland, Michigan, Missouri, New York, North Carolina, Oregon, Pennsylvania
2018-04-09
Active, closed
PARTNER 3 Trial - Mitral Valve in Valve
NCT03193801Mitral Valve Insufficiency, Mitral Valve Disease, Mitral Valve Regurgitation, Heart Failure
Edwards Lifesciences
Not applicable
53
Georgia, Illinois, Massachusetts, Minnesota, Missouri, New York, Oregon, Texas
2018-02-01
Recruiting
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
NCT03373968Duchenne Muscular Dystrophy
DrugHydroxyurea
Italfarmaco
Phase 2/3
206
California, Connecticut, Florida, Georgia, Iowa, Missouri, Oregon, Pennsylvania
2017-10-24
Active, closed
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552Non-Small Cell Lung Cancer
DrugsCobimetinib·Divarasib·Vemurafenib·Entrectinib
Hoffmann-La Roche
Phase 2/3
1,000
California, Colorado, Florida, Kentucky, Nevada, New Hampshire, New York, Oregon
2017-09-22
Active, closed
Prospective G7 Dual Mobility Total Hip PMCF
NCT03308929Clinical Outcomes, Functional Outcomes, Radiological Outcomes, Survivorship
Zimmer Biomet
Observational
250
New Jersey, New Mexico, North Carolina, Oregon, Virginia
2017-02-28
Active, closed
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
NCT03069469Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor
DrugVimseltinib
Deciphera Pharmaceuticals, LLC
Phase 1/2
120
California, Colorado, Florida, Massachusetts, New York, Oregon, Tennessee
2017-02-16
Active, closed
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
NCT02477878Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
DrugRimiducid
Bellicum Pharmaceuticals
Phase 1
10
Georgia, Kansas, New York, Oregon, Texas
2016-07
By invitation
Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency
NCT02796937Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
Grifols Therapeutics LLC
Phase 3
290
Arizona, Florida, North Carolina, Oregon, South Carolina, Texas
2016-07
Active, closed
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
NCT02767804Non-small Cell Lung Cancer
DrugsEnsartinib·Crizotinib
Xcovery Holdings, Inc.
Phase 3
290
Florida, Georgia, Missouri, Oregon
2016-06
Active, closed
On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study
NCT02677974Thrombotic and Bleeding Events
On-X Life Technologies, Inc.
Observational
510
Arizona, Connecticut, Indiana, Maine, North Dakota, Ohio, Oregon, Texas
2015-11-10
Active, closed
LEGION Hinge Safety and Efficacy Study
NCT02445443Knee Arthroplasty, Total
Smith & Nephew, Inc.
Observational
47
Iowa, New York, Oregon
2015-06-30
Active, closed
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
NCT03301168Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
DrugsBPX-501 T cells·Rimiducid
Bellicum Pharmaceuticals
Phase 1/2
120
California, District of Columbia, Georgia, Massachusetts, New York, Oregon, Texas, Washington
2014-04
Active, closed
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
NCT02057133Breast Neoplasms
DrugsLoperamide·Samotolisib·Tamoxifen·Exemestane
Eli Lilly and Company
Phase 1
198
Arkansas, California, Massachusetts, Minnesota, New York, North Carolina, Oregon, Pennsylvania
2014-03-10
Active, closed
A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
NCT02065011Usher's Syndrome
Sanofi
Phase 2
9
Oregon
2013-09-12
Active, closed
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
NCT01744223Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
DrugRimiducid
Bellicum Pharmaceuticals
Phase 1/2
36
Georgia, New York, Ohio, Oregon, Texas, Washington
2013-03
Active, closed
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
NCT01687608Hemophilia B
Baxalta now part of Shire
Phase 1/2
30
California, Colorado, Georgia, Illinois, Massachusetts, Minnesota, New York, Oregon
2013-02-11
Active, closed
Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
NCT01736592Stargardt's Disease
Sanofi
Phase 2
27
Oregon
2012-12-14
Active, closed
A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
NCT01678872Age-Related Macular Degeneration
Oxford BioMedica
Phase 1
18
Iowa, Maryland, Oregon
2012-08
Active, closed
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
NCT01081951Ovarian Cancer
DrugsTaxol·Olaparib·Paclitaxel·Carboplatin
AstraZeneca
Phase 2
162
California, Florida, Indiana, Massachusetts, New York, Oregon
2010-02-04
Rows per page Showing 1–345 of 345
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/oregon

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 345 of those studies with a site in Oregon.

How many clinical trials are recruiting in Oregon?

173 of the 345 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 8 have not yet opened recruitment, 153 are active but closed to new participants, and 11 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Oregon), 345 studies
PhaseStudiesRecruitingShare
Phase 1/2703920.3%
Phase 1613417.7%
Phase 2562316.2%
Phase 3512614.8%
Not applicable502314.5%
Observational441912.8%
Phase 2/3742%
Phase 4551.4%
Phase EARLY_PHASE1100.3%

Most active sponsors

Lead sponsors with the most studies (Oregon)
Lead sponsorStudiesRecruiting
AstraZeneca149
Novartis Pharmaceuticals125
Bristol-Myers Squibb97
AbbVie84
Janssen Research & Development, LLC83
Merck Sharp & Dohme LLC75
Zimmer Biomet71
Edwards Lifesciences50
Regeneron Pharmaceuticals53
Beacon Therapeutics40
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.